检验医学 ›› 2023, Vol. 38 ›› Issue (7): 696-703.DOI: 10.3969/j.issn.1673-8640.2023.07.015
收稿日期:
2021-10-08
修回日期:
2022-06-20
出版日期:
2023-07-30
发布日期:
2023-09-18
通讯作者:
李英华,E-mail:liyinghua@gzhmu.edu.cn。
作者简介:
陈丹阳,女,1997年生,硕士,主要从事临床病毒病原学研究。
CHEN Danyang, ZHENG Siyu, ZHENG Ruilin, SU Jingyao, ZHU Bing, LI Yinghua()
Received:
2021-10-08
Revised:
2022-06-20
Online:
2023-07-30
Published:
2023-09-18
摘要:
流行性感冒(简称流感)是由流感病毒感染所致的具有高度传染性的急性呼吸道疾病,具有强致病性和高病死率。近年来,针对流感病毒的研究已取得了一定的进展,但流感病毒的药物和疫苗研发仍存在不足。目前,对于流感病毒的发展趋势和病毒变异情况尚无法预测,仍需广大科研工作者对流感病毒的病原学和致病机制进行深入研究。文章就流感病毒的病原学、流行病学、致病机制、流感相关性肺炎和急性呼吸窘迫综合征、药物研发等进行综述。
中图分类号:
陈丹阳, 郑思钰, 郑锐林, 苏静瑶, 朱冰, 李英华. 流感病毒研究进展[J]. 检验医学, 2023, 38(7): 696-703.
CHEN Danyang, ZHENG Siyu, ZHENG Ruilin, SU Jingyao, ZHU Bing, LI Yinghua. Research progress in influenza viruses[J]. Laboratory Medicine, 2023, 38(7): 696-703.
RNA片段① | 编码的蛋白质 | 蛋白质功能 |
---|---|---|
1 | PB2 | RNA聚合酶组分,参与病毒遗传物质的复制和转录 |
2 | PB1 | RNA聚合酶组分,参与病毒遗传物质的复制和转录 |
3 | PA | RNA聚合酶组分,参与病毒遗传物质的复制和转录 |
4 | HA | 血凝素,介导病毒吸附和病毒包膜-内体膜融合 |
5 | NP | 核蛋白,参与构成核糖核蛋白,参与病毒RNA的合成 |
6 | NA | 神经氨酸酶,清除细胞表面的唾液酸,防止病毒颗粒聚集,促进病毒的释放 |
7 | MP(包括M1、M2) | M1为基质蛋白,促进病毒装配,维持病毒的形态;M2为离子通道型跨膜蛋白,促进病毒脱壳 |
8 | NS(包括NS1、NS2) | 非结构蛋白;NS1可抑制mRNA前体的拼接和干扰素产生,NS2可促进病毒RNA的表达及转运。 |
表1 流感病毒RNA片段编码的蛋白质及其功能
RNA片段① | 编码的蛋白质 | 蛋白质功能 |
---|---|---|
1 | PB2 | RNA聚合酶组分,参与病毒遗传物质的复制和转录 |
2 | PB1 | RNA聚合酶组分,参与病毒遗传物质的复制和转录 |
3 | PA | RNA聚合酶组分,参与病毒遗传物质的复制和转录 |
4 | HA | 血凝素,介导病毒吸附和病毒包膜-内体膜融合 |
5 | NP | 核蛋白,参与构成核糖核蛋白,参与病毒RNA的合成 |
6 | NA | 神经氨酸酶,清除细胞表面的唾液酸,防止病毒颗粒聚集,促进病毒的释放 |
7 | MP(包括M1、M2) | M1为基质蛋白,促进病毒装配,维持病毒的形态;M2为离子通道型跨膜蛋白,促进病毒脱壳 |
8 | NS(包括NS1、NS2) | 非结构蛋白;NS1可抑制mRNA前体的拼接和干扰素产生,NS2可促进病毒RNA的表达及转运。 |
[1] |
KALIL A C, THOMAS P G. Influenza virus-related critical illness:pathophysiology and epidemiology[J]. Crit Care, 2019, 23(1):258.
DOI |
[2] | CHAISRI U, CHAICUMPA W. Evolution of therapeutic antibodies,influenza virus biology,influenza,and influenza immunotherapy[J]. Biomed Res Int, 2018, 2018:9747549. |
[3] |
SHAHAM A, CHODICK G, SHALEV V, et al. Personal and social patterns predict influenza vaccination decision[J]. BMC Public Health, 2020, 20(1):222.
DOI PMID |
[4] |
BAILEY E S, CHOI J Y, FIELDHOUSE J K, et al. The continual threat of influenza virus infections at the human-animal interface:what is new from a one health perspective?[J]. Evol Med Public Health, 2018, 2018(1):192-198.
DOI URL |
[5] |
KRAMMER F, SMITH G J D, FOUCHIER R A M, et al. Influenza[J]. Nat Rev Dis Primers, 2018, 4(1):3.
DOI PMID |
[6] |
SAUNDERS-HASTINGS P R, KREWSKI D. Reviewing the history of pandemic influenza:understanding patterns of emergence and transmission[J]. Pathogens, 2016, 5(4):66.
DOI URL |
[7] |
TRAN D, VAUDRY W, MOORE D, et al. Hospitalization for influenza A versus B[J]. Pediatrics, 2016, 138(3):e20154643.
DOI URL |
[8] |
FLERLAGE T, BOYD D F, MELIOPOULOS V, et al. Influenza virus and SARS-CoV-2:pathogenesis and host responses in the respiratory tract[J]. Nat Rev Microbiol, 2021, 19(7):425-441.
DOI |
[9] |
LAZNIEWSKI M, DAWSON W K, SZCZEPINSKA T, et al. The structural variability of the influenza A hemagglutinin receptor-binding site[J]. Brief Funct Genomics, 2018, 17(6):415-427.
DOI PMID |
[10] |
DU W, DE VRIES E, VAN KUPPEVELD F J M, et al. Second sialic acid-binding site of influenza A virus neuraminidase:binding receptors for efficient release[J]. FEBS J, 2021, 288(19):5598-5612.
DOI URL |
[11] |
TAVARES L P, TEIXEIRA M M, GARCIA C C. The inflammatory response triggered by influenza virus:a two edged sword[J]. Inflamm Res, 2017, 66(4):283-302.
DOI |
[12] | RAMOS I, FERNANDEZ-SESMA A. Modulating the innate immune response to influenza A virus:potential therapeutic use of anti-inflammatory drugs[J]. Front Immunol, 2015, 6:361. |
[13] |
BOWIE A G, UNTERHOLZNER L. Viral evasion and subversion of pattern-recognition receptor signalling[J]. Nat Rev Immunol, 2008, 8(12):911-922.
DOI PMID |
[14] |
DUAN M, HIBBS M L, CHEN W. The contributions of lung macrophage and monocyte heterogeneity to influenza pathogenesis[J]. Immunol Cell Biol, 2017, 95(3):225-235.
DOI PMID |
[15] |
KOSTADINOVA E, CHAPUT C, GUTBIER B, et al. NLRP3 protects alveolar barrier integrity by an inflammasome-independent increase of epithelial cell adherence[J]. Sci Rep, 2016, 6:30943.
DOI PMID |
[16] |
TAN K S, LIM R L, LIU J, et al. Respiratory viral infections in exacerbation of chronic airway inflammatory diseases:novel mechanisms and insights from the upper airway epithelium[J]. Front Cell Dev Biol, 2020, 8:99.
DOI URL |
[17] | LAMICHHANE P P, SAMARASINGHE A E. The role of innate leukocytes during influenza virus infection[J]. J Immunol Res, 2019, 2019:8028725. |
[18] |
LI K, MCCAW J M, CAO P. Modelling within-host macrophage dynamics in influenza virus infection[J]. J Theor Biol, 2021, 508:110492.
DOI URL |
[19] |
HÖGNER K, WOLFF T, PLESCHKA S, et al. Correction:macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia[J]. PLoS Pathog, 2016, 12(6):e1005716.
DOI URL |
[20] |
WANG X, SUN Q, YE Z, et al. Computational approach for predicting the conserved B-cell epitopes of hemagglutinin H7 subtype influenza virus[J]. Exp Ther Med, 2016, 12(4):2439-2446.
PMID |
[21] |
AMPOMAH P B, LIM L H K. Influenza A virus-induced apoptosis and virus propagation[J]. Apoptosis, 2020, 25(1-2):1-11.
DOI PMID |
[22] |
ATKIN-SMITH G K, DUAN M, CHEN W, et al. The induction and consequences of influenza A virus-induced cell death[J]. Cell Death Dis, 2018, 9(10):1002.
DOI |
[23] |
WANG R, ZHU Y, REN C, et al. Influenza A virus protein PB1-F2 impairs innate immunity by inducing mitophagy[J]. Autophagy, 2021, 17(2):496-511.
DOI URL |
[24] | MAYANK A K, SHARMA S, NAILWAL H, et al. Nucleoprotein of influenza A virus negatively impacts antiapoptotic protein API5 to enhance E2F1-dependent apoptosis and virus replication[J]. Cell Death Dis, 2015, 6(12): e2018. |
[25] | EL-SAYED I, BASSIOUNY K, NOKALY A, et al. Influenza A virus and influenza B virus can induce apoptosis via intrinsic or extrinsic pathways and also via NF-κB in a time and dose dependent manner[J]. Biochem Res Int, 2016, 2016:1738237. |
[26] |
WANG X, TAN J, ZOUEVA O, et al. Novel pandemic influenza A(H1N1)virus infection modulates apoptotic pathways that impact its replication in A549 cells[J]. Microbes Infect, 2014, 16(3):178-186.
DOI URL |
[27] |
LAM W Y, TANG J W, YEUNG A C, et al. Avian influenza virus A/HK/483/97(H5N1)NS1 protein induces apoptosis in human airway epithelial cells[J]. J Virol, 2008, 82(6):2741-2751.
DOI URL |
[28] |
ZHANG T, YIN C, BOYD D F, et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis[J]. Cell, 2020, 180(6):1115-1129.
DOI PMID |
[29] |
LAGHLALI G, LAWLOR K E, TATE M D. Die another way:interplay between influenza a virus,inflammation and cell death[J]. Viruses, 2020, 12(4):401.
DOI URL |
[30] | BALACHANDRAN S, RALL G F. Benefits and perils of necroptosis in influenza virus infection[J]. J Virol, 2020, 94(9):e01101- e01119. |
[31] |
NOGUSA S, THAPA R J, DILLON C P, et al. RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza A virus[J]. Cell Host Microbe, 2016, 20(1):13-24.
DOI PMID |
[32] |
YATIM N, CULLEN S, ALBERT M L. Dying cells actively regulate adaptive immune responses[J]. Nat Rev Immunol, 2017, 17(4):262-275.
DOI PMID |
[33] | GABA A, XU F, LU Y, et al. The NS1 protein of influenza A virus participates in necroptosis by interacting with MLKL and increasing its oligomerization and membrane translocation[J]. J Virol, 2019, 93(2):e01835-18. |
[34] |
HEO J Y, SONG J Y, NOH J Y, et al. Effects of influenza immunization on pneumonia in the elderly[J]. Hum Vaccin Immunother, 2018, 14(3):744-749.
DOI URL |
[35] | METERSKY M L, MASTERTON R G, LODE H, et al. Epidemiology,microbiology,and treatment considerations for bacterial pneumonia complicating influenza[J]. Int J Infect Dis, 2012, 16(5):e321-e331. |
[36] |
WYPYCH T P, WICKRAMASINGHE L C, MARSLAND B J. The influence of the microbiome on respiratory health[J]. Nat Immunol, 2019, 20(10):1279-1290.
DOI PMID |
[37] |
METZGER D W, SUN K. Immune dysfunction and bacterial coinfections following influenza[J]. J Immunol, 2013, 191(5):2047-2052.
DOI PMID |
[38] | BAL A, CASALEGNO J S, MELENOTTE C, et al. Influenza-induced acute respiratory distress syndrome during the 2010-2016 seasons:bacterial co-infections and outcomes by virus type and subtype[J]. Clin Microbiol Infect, 2020, 26(7):947.e1-947.e4. |
[39] |
XU J, YU J, YANG L, et al. Influenza virus in community-acquired pneumonia:current understanding and knowledge gaps[J]. Semin Respir Crit Care Med, 2020, 41(4):555-567.
DOI URL |
[40] |
BRAND J D, LAZRAK A, TROMBLEY J E, et al. Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis[J]. JCI Insight, 2018, 3(20):e123467.
DOI URL |
[41] |
GUO X J, THOMAS P G. New fronts emerge in the influenza cytokine storm[J]. Semin Immunopathol, 2017, 39(5):541-550.
DOI |
[42] |
SHIE J J, FANG J M. Development of effective anti-influenza drugs:congeners and conjugates-a review[J]. J Biomed Sci, 2019, 26(1):84.
DOI |
[43] |
HANSHAOWORAKUL W, SIMMERMAN J M, NARUEPONJIRAKUL U, et al. Severe human influenza infections in Thailand:oseltamivir treatment and risk factors for fatal outcome[J]. PLoS One, 2009, 4(6):e6051.
DOI URL |
[44] |
LI Y, LIN Z, ZHAO M, et al. Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways[J]. ACS Appl Mater Interfaces, 2016, 8(37):24385-24393.
DOI URL |
[45] |
LI Y, LIN Z, GUO M, et al. Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus[J]. Int J Nanomedicine, 2017, 12:5733-5743.
DOI URL |
[46] |
LI Y, LIN Z, GUO M, et al. Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways[J]. Int J Nanomedicine, 2018, 13:2005-2016.
DOI URL |
[47] |
LIN Z, LI Y, GONG G, et al. Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway[J]. Int J Nanomedicin, 2018, 13:5787-5797.
DOI URL |
[1] | 赵若楠, 盛哲, 叶志成, 杨丹, 余先智. 上海某儿科医院新型冠状病毒肺炎疫情前后腹泻患儿A组轮状病毒流行特征[J]. 检验医学, 2023, 38(9): 890-892. |
[2] | 武晋英, 方玉莲, 王维, 侯梦珠, 王露, 赵煜. 天津地区急性腹泻患儿肠道病毒感染临床特征和流行病学分析[J]. 检验医学, 2023, 38(3): 267-271. |
[3] | 胡韶华, 陈黎, 赵梦, 马展, 张泓. 上海地区儿童肺炎支原体感染流行病学特征分析[J]. 检验医学, 2023, 38(1): 14-17. |
[4] | 吴江, 杨为斌. 血管生成素2、克拉拉细胞蛋白16和肺血管通透性指数在ARDS中的临床应用价值[J]. 检验医学, 2023, 38(1): 73-75. |
[5] | 刘婧娴, 陈星月, 赵晶, 刘瑛. 非妊娠成人无乳链球菌感染临床特点及分子流行病学研究进展[J]. 检验医学, 2022, 37(8): 793-797. |
[6] | 钟丽红, 丘创华, 彭紫元, 佘吉佳. 脂毒性应激对Bcl-2蛋白诱导胰岛β细胞凋亡的调节作用[J]. 检验医学, 2022, 37(3): 274-280. |
[7] | 唐钧, 曹红梅. 甲型H1N1流感病毒RNA检测方法的建立及临床应用[J]. 检验医学, 2021, 36(7): 738-742. |
[8] | 郭卫东, 付云, 高尚兰. 血浆APN、sRAGE与ARDS患者预后的关系[J]. 检验医学, 2021, 36(11): 1097-1100. |
[9] | 黄韵, 李从荣. 高毒力肺炎克雷伯菌研究进展[J]. 检验医学, 2021, 36(11): 1181-1185. |
[10] | 陈家旭, 蔡玉春, 艾琳, 宋鹏, 陈木新, 陈韶红, 卢艳, 周晓农. 我国重要人体寄生虫病防控现状与挑战[J]. 检验医学, 2021, 36(10): 993-1000. |
[11] | 梁翠琼, 汤美玲, 谢治华. 深圳市某院病毒性腹泻患儿病原分布及季节流行特征[J]. 检验医学, 2020, 35(9): 868-871. |
[12] | 闫江泓, 贾莉, 李文辉, 杨硕, 严小桐, 赵梦川, 郭巍巍, 刘颖业, 刘泽昊, 王乐. 河北省儿童医院住院患儿EB 病毒感染流行病学特征[J]. 检验医学, 2020, 35(4): 323-326. |
[13] | 马洲, 关明, 邢志芳, 曹国君. 流感病毒研究现状与进展[J]. 检验医学, 2020, 35(12): 1315-1319. |
[14] | 付晓蕊, 康蓓佩, 徐修礼, 赵峰, 张鹏亮, 周磊. 快速病原体检测技术在甲型流感病毒检测中的应用[J]. 检验医学, 2020, 35(11): 1165-1168. |
[15] | 王辉, 周爱萍, 吴文娟. 上海市某教学医院淋病奈瑟菌耐药特征及耐药机制[J]. 检验医学, 2019, 34(9): 795-799. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||